Drug Profile
Research programme: cancer therapies - Delphian Pharmaceuticals
Latest Information Update: 20 Sep 2011
Price :
$50
*
At a glance
- Originator Delphian Pharmaceuticals
- Class
- Mechanism of Action Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Jul 2007 Preclinical trials in Cancer in USA (unspecified route)